Zynerba (NASDAQ: ZYNE) is dedicated to improving the lives of people with rare and near rare neuropsychiatric disorders where there is a high unmet medical need by pioneering the development and commercialization of next-generation pharmaceutically-produced cannabinoid therapeutics formulated for transdermal delivery. Cannabinoids interact with specific receptors throughout the body to produce pharmacologic effects, primarily in the CNS and immune systems.
Transdermal delivery has the potential to reduce adverse effects associated with oral dosing because it allows the drug to be absorbed through the skin directly into the bloodstream, avoiding the gastrointestinal tract and lessening the opportunity for GI-related adverse events. It also avoids first-pass liver metabolism, potentially enabling lower dosage levels of active pharmaceutical ingredients with a higher bioavailability and an improved safety profile.
Zynerba’s lead patent-protected product candidate in clinical development is Zygel™ (formerly known as ZYN002):
Zygel is the first and only pharmaceutically-produced cannabidiol (CBD) formulated as a permeation-enhanced gel for transdermal delivery. Through a proprietary combination of our pharmaceutically-produced CBD and permeation enhancers, we believe we can effectively deliver CBD through the layers of the epidermis and into the circulatory system. The company is currently assessing Zygel in Fragile X Syndrome, Autism Spectrum Disorder, a rare genetic neuropsychiatric syndrome called 22q11.2 Deletion Syndrome, and a heterogeneous group of rare and ultra-rare epilepsy syndromes associated with severe cognitive impairment and behavioral disturbances known as developmental and epileptic encephalopathies (DEE).
Cannabinoids appear to modulate a number of systems, channels and receptors; as such, they may have the potential to be developed in a number of additional important indications, including anxiety, autism spectrum disorder, neuroprotection, cognitive disorders, sleep disturbance, and treatment for certain neuralgias.
Jim Fickenscher: Jim Fickenscher serves as Zynerba’s Chief Financial Officer, Vice President, Corporate Development. Mr. Fickenscher is a seasoned executive who has held management, financial and strategic planning roles in his 28-year tenure in the pharmaceutical industry. Prior to Zynerba, he was Senior Vice President, Chief Financial Officer, at Antares Pharma (NASDAQ: ATRS), a commercial pharmaceutical company focused on self-administered parenteral products. He has also held the role of Chief Financial Officer at both Auxilium Pharmaceuticals (NASDAQ: AUXL) and Aventis Behring, as well as additional general management, business development and strategic planning responsibilities. Mr. Fickenscher holds a BS from Bloomsburg University of Pennsylvania. He is also a Member of the American Institute of Certified Public Accountants.
Will Roberts | Vice President, Investor relations and Corporate [email protected] Pharmaceuticals
Will Roberts: Will Roberts serves as our Vice President, Investor Relations and Corporate Communications. Mr. Roberts is a successful communications officer with 25 years of biotechnology/pharmaceutical experience in corporate communications, investor and public relations and preclinical research. Prior to Zynerba, he served as Vice President, Investor Relations and Corporate Communications for Adaptimmune Therapeutics plc (NASDAQ: ADAP), where he supported the company’s May 2015 IPO and developed the company’s communications strategies. He spent 10 years with ViroPharma Inc. (NASDAQ: VPHM), a biotechnology company routinely recognized for excellence in investor relations and communications, culminating in his tenure as Vice President, Corporate Communications. There he was responsible for leading global investor and corporate communications, patient advocacy, disease awareness programming and global communications support for the company’s marketed products. Mr. Roberts began his professional career at MedImmune, Inc. (NASDAQ: MEDI) in 1992. He spent 12 years with the company, transitioning from his initial role as a molecular microbiology research scientist into investor relations in 1997. Mr. Roberts received a B.A. in biology from the University of Virginia, and an M.B.A. from the Keller Graduate School of Management.